Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Advisory Committee on Immunization Practices (ACIP)


Section Navigation
			
			CDC Home








Evidence to Recommendations Frameworks						Print
																Related Pages
										The following are the Evidence to Recommendations (EtR) frameworks that describe information considered in moving from evidence to ACIP vaccine recommendations.
The purpose of EtR frameworks is to help panels making recommendations move from evidence to decisions, and to provide transparency around the impact of additional factors on deliberations when considering a recommendation. These tables accompany ACIP recommendations published in the Morbidity and Mortality Weekly Reports (MMWR).
List of Evidence to Recommendations Framework Tables
Listed in most recently published order.
ACIP Evidence to Recommendations for Primary Polio Vaccination Among Adults Aged ≥18 YearsLinked from MMWR; December 7, 2023 / 72(49);1327–1330
ACIP Evidence to Recommendations for Booster Doses of Inactivated Poliovirus Vaccine (IPV) Among Adults Aged ≥18 YearsLinked from MMWR; December 7, 2023 / 72(49);1327–1330
ACIP Evidence to Recommendations Framework for Tick-Borne Encephalitis (TBE) Vaccination for Persons Who Travel AbroadLinked from MMWR; November 10, 2023 / 72(5);1–29
ACIP Evidence to Recommendations Framework for Tick-Borne Encephalitis (TBE) Vaccination for Laboratory WorkersLinked from MMWR; November 10, 2023 / 72(5);1–29
EtR framework for Use of an Updated (Monovalent XBB Containing) COVID-19 Vaccine Under an Emergency Use Authorization | CDCLinked from MMWR; October 20, 2023 / 72(42);1140-1146
ACIP Evidence to Recommendations for Use of Pfizer RSVpreF in Pregnant People | CDCLinked from MMWR; October 13, 2023 / 72(41);1115-1122
EtR framework for PCV20 use in children aged 2–18 years with certain underlying conditions that increase the risk of pneumococcal diseaseLinked from MMWR; September 29, 2023 / 72(39);1072
EtR framework for PCV20 use in children aged <2 yearsLinked from MMWR; September 29, 2023 / 72(39);1072
EtR Framework for Adults Aged 19–64 Years With an Immunocompromising Condition, Cochlear Implant, or Cerebrospinal Fluid Leak Who Have Previously Received Both PCV13 and PPSV23Linked from MMWR; September 8, 2023 / 72(3);1–39
EtR Framework for Adults Aged ≥65 Years Who Have Previously Received Both PCV13 and PPSV23Linked from MMWR; September 8, 2023 / 72(3);1–39
EtR Framework for Adults Aged ≥19 Years Who Have Previously Received PCV13 OnlyLinked from MMWR; September 8, 2023 / 72(3);1–39
EtR for Use of Nirsevimab in Infants <8 months of age born during the RSV season or entering their first RSV seasonLinked from MMWR; August 25, 2023 / 72(34);920–925
EtR for Use of Nirsevimab in Children 8–19 months of age at increased risk of severe disease entering their second RSV seasonLinked from MMWR; August 25, 2023 / 72(34);920–925
Evidence to Recommendations (EtR) Framework: Safety of Influenza Vaccines for Persons with Egg AllergyLinked from MMWR; August 25, 2023 / 72(2);1–25
EtR for Use of GSK Adjuvanted RSVPreF3 Vaccine (AREXVY) in Adults Ages 60 and OlderLinked from MMWR; July 21, 2023 / 72(29);793–801
EtR for Use of Pfizer Bivalent RSVpreF Vaccine (ABRSYVO) in Adults Ages 60 and OlderLinked from MMWR; July 21, 2023 / 72(29);793–801
EtR for use of PRIORIX for Prevention of Measles, Mumps, and RubellaLinked from MMWR; November 18, 2022/ 71(46); 1465–1470
EtR for Use of Bivalent COVID-19 Vaccine Booster Doses under an Emergency Use AuthorizationLinked from MMWR; November 11, 2022/ 71(45); 1436-1441
EtR for Use of Novavax COVID-19 Vaccine Booster Dose for adults ages 18 years and older under an Emergency Use AuthorizationLinked from MMWR; November 11, 2022/ 71(45); 1436-1441
EtR Framework for Use of Lyophilized CVD 103-HgR Vaccine Among Children and Adolescents Aged 2–17 yearsLinked from MMWR; September 30, 2022 / 71(2);1–8
EtR Framework for PCV15 use in children aged <2 yearsLinked from MMWR; September 16, 2022 / 71(37);1174–1181
EtR Framework for PCV15 use in children aged 2–18 years with certain underlying medical conditions that increase the risk of pneumococcal diseaseLinked from MMWR; September 16, 2022 / 71(37);1174–1181
EtR Framework for Higher Dose and Adjuvanted Influenza Vaccines for Persons Aged ≥65 YearsLinked from MMWR; August 26, 2022 / 71(1);1–28
ACIP Evidence to Recommendations for Use of Novavax COVID-19 Vaccine, Adjuvanted in adults ages 18 years and older under an Emergency Use Authorization (cdc.gov)Linked from MMWR; August 4, 2022/ 71(31); 988-992
ACIP Evidence to Recommendations for Use of Moderna COVID-19 Vaccine in Children Ages 6 – 11 years and Adolescents Ages 12 – 17 years under an Emergency Use Authorization
ACIP Evidence to Recommendations for Use of Moderna COVID-19 Vaccine in Children Ages 6 Months – 5 Years and Pfizer-BioNTech COVID-19 Vaccine in Children Ages 6 Months – 4 Years under an Emergency Use AuthorizationLinked from MMWR; June 28, 2022/ 71(26)
EtR for Use of JYNNEOS (orthopoxvirus) Vaccine Heterologous for Those Who Received ACAM2000 Primary Series (Policy Question 5)Linked from MMWR; June 3, 2022 / 71(22);734–742
EtR for Use of JYNNEOS (orthopoxvirus) Vaccine Primary Series for Research, Clinical Laboratory, and Response Team Personnel (Policy Question 1)Linked from MMWR; June 3, 2022 / 71(22);734–742
EtR for Use of JYNNEOS (orthopoxvirus) Vaccine Primary Series for Healthcare Personnel (Policy Question 2)Linked from MMWR; June 3, 2022 / 71(22);734–742
EtR Update for a Pfizer-BioNTech COVID-19 Booster in Children Ages 5-11 Years
EtR Framework for a 2nd COVID-19 Booster Dose in Adults Ages 50 Years and Older and Immunocompromised Individuals
EtR Framework for Rabies Pre-exposure prophylaxis with a 2-dose ScheduleLinked from MMWR; May 6, 2022 / 71(18);619–627
EtR Framework for a Booster Dose of Rabies Vaccine After the 2-dose Pre-exposure Prophylaxis ScheduleLinked from MMWR; May 6, 2022 / 71(18);619–627
EtR Framework for a Universal Hepatitis B (HepB) Vaccination Strategy in AdultsLinked from MMWR; April 1, 2022 / 71(13);477–483
EtR Framework for use of PreHevbrio Hepatitis B (HepB) Vaccine in AdultsLinked from MMWR; April 1, 2022 / 71(13);477–483
EtR Framework for Moderna COVID-19 VaccineLinked from MMWR; March 18, 2022 / 71(11);416–421
EtR Framework for PCV20 Use Among Adults 19-64 Years OldLinked from MMWR; January 28, 2022 / 71(4);109–117
EtR Framework for PCV20 Use Among Adults ≥65 Years OldLinked from MMWR; January 28, 2022 / 71(4);109–117
EtR Framework for PCV15 Use Among Adults 19-64 Years OldLinked from MMWR; January 28, 2022 / 71(4);109–117
EtR Framework for PCV15 Use Among Adults ≥65 Years OldLinked from MMWR; January 28, 2022 / 71(4);109–117
EtR Framework for Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 YearsLinked from MMWR; January 21, 2022 / 71(3);80–84
EtR Framework for DengvaxiaLinked from MMWR; December 17, 2021 / 70(6);1–16
EtR Framework for Use of an Additional COVID-19 Vaccine Dose in Immunocompromised PeopleLinked from MMWR; October 29, 2021 / 70(44)
EtR Framework for Use of COVID-19 Vaccine Booster DosesLinked from MMWR; October 29, 2021 / 70(44)
EtR Framework for Use of Janssen COVID-19 Vaccine under an Emergency Use AuthorizationLinked from MMWR; March 2, 2021 / 70(9);329–332
EtR Framework for Use of rVSVΔG-ZEBOV-GP Ebola vaccine for persons in the U.S. population who are at potential occupational risk of exposure to Ebola virusLinked from MMWR; January 8, 2021 / 70(1);1–12
EtR Framework for Use of Moderna COVID-19 Vaccine under an Emergency Use AuthorizationLinked from MMWR; January 1, 2021 / 69(5152);1653-1656
EtR Framework for Use of Pfizer-BioNTech COVID-19 Vaccine under an Emergency Use AuthorizationLinked from MMWR; December 18, 2020 / 69(50);1922-1924
EtR Framework for MenACWY-TT (MenQuadfi) Meningococcal VaccineLinked from MMWR; September 25, 2020 / 69(9);1–41
EtR Framework for Serogroup B Meningococcal Vaccine Booster DoseLinked from MMWR; September 25 / 69(9);1–41
EtR Framework for Serogroup B Meningococcal Vaccine Booster Dose During an OutbreakLinked from MMWR; September 25 / 69(9);1–41
EtR Framework for Hepatitis A Vaccine Catch-upLinked from MMWR; July 3, 2020 / 69(5);1–38
EtR Framework for Hepatitis A Vaccine for Persons With HIVLinked from MMWR; July 3, 2020 / 69(5);1–38
EtR Framework for Tdap Vaccines in Adolescents and AdultsLinked from MMWR; January 24, 2020 / 69(3);77–83
EtR Framework for PCV13 use among adults ≥65 years oldLinked from MMWR; November 22, 2019 / 68(46);1069–75
EtR Framework for HPV Vaccination of Adults, Ages 27 through 45 yearsLinked from MMWR; August 16, 2019 / 68(32);698–702
EtR Framework for HPV Vaccination Harmonization across Genders, Ages 22 through 26 yearsLinked from MMWR; August 16, 2019 / 68(32);698–702
EtR Framework for Japanese Encephalitis VaccineLinked from MMWR; July 19, 2019 / 68(2);1–33
EtR framework for PCV20 use in children aged 2–18 years with certain underlying conditions that increase the risk of pneumococcal diseaseLinked from MMWR; September 29, 2023 / 72(39);1072
EtR framework for PCV20 use in children aged <2 yearsLinked from MMWR; September 29, 2023 / 72(39);1072
							
					
							Last Reviewed:  December 6, 2023						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeACIP Home
Meeting Information
Committee Informationplus icon
Role of the ACIP in CDC’s Vaccine Recommendations
Charter
Economics Studies
Committee Membersplus icon
ACIP Membership Roster
Apply for ACIP Membership
Work Groupsplus icon
VaST Reportsplus icon
June 28, 2021
May 24, 2021
May 17, 2021
March 29, 2021
Recommendationsplus icon
Shared Clinical Decision-Making Recommendations
Evidence Based Recommendationsplus icon
About GRADE
Grade Evidence Tables
Evidence to Recommendations Frameworks Vaccines & ImmunizationsImmunization SchedulesVFC ResolutionsVaccine Information Statements (VISs)
  1600 Clifton Road, N.E., Mailstop A27
Atlanta, GA 30329-4027acip@cdc.gov


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue